Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent chromium in rheumatoid arthritis
NCT05545020Phase 3Completed
- Sponsor
- Alexandria University
- Start
- Dec 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of chromium in rheumatoid arthritis (RA) (2 arms), sponsored by Alexandria University. Primary endpoints: Disease Activity Score 28 at 12 weeks, Erythrocyte Sedimentation Rate at 12 weeks and 2 more. Started Dec 2022; status: completed.
02
Drugs
chromium
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05545020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545020.